Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 20;13(4):99-101.
doi: 10.5493/wjem.v13.i4.99.

Update on hydroxychloroquine use in pregnancy

Wassan Nori  1 , Nabeeha Najatee Akram  2 , Raid M Al-Ani  3
Affiliations

Update on hydroxychloroquine use in pregnancy

Wassan Nori et al. World J Exp Med. .

Abstract

It is well-known that hydroxychloroquine (HCQ) treats malaria, systemic lupus erythematosus, and rheumatoid arthritis in women for its immunomodulatory and anti-inflammatory action. Additionally, HCQ was used in cases with refractory antiphospholipid syndrome. HCQ safety was reinforced in pregnant women owing to insignificant reports of adverse pregnancy outcomes and major congenital malformation. Recently, HCQ was tested in cases with chronic placental inflammation with a promising result of increased life birth; however, its benefit needs further validation. We aimed to highlight the recent updates for HCQ use in various conditions in pregnancy.

Keywords: Antiphospholipid syndrome; COVID-19; Chronic placental inflammation; Hydroxychloroquine; Preeclampsia; Pregnancy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Similar articles

See all similar articles

Cited by

References

    1. Bajpai J, Pradhan A, Verma AK, Kant S. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. World J Exp Med. 2022;12:44–52. - PMC - PubMed
    1. Clowse MEB, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz R, Gladman DD, Molad Y, Nalli C, Mokbel A, Tincani A, Urowitz M, Bay C, van Noord M, Petri M. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022;9 - PMC - PubMed
    1. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72:529–556. - PubMed
    1. Nori W, Shallal F, Zghair MAG. Aspirin effect on Mid luteal Phase Doppler Indices in Patients with Recurrent Pregnancy Loss. Int J Pharm Res. 2020;12:2929–2934.
    1. Saraiva-Mangolin S, Vaz CO, Ruiz T, Mazetto BM, Orsi FA. Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome. Eur J Intern Med. 2021;90:114–115. - PubMed